期刊文献+

ICE方案治疗复发和难治性非霍奇金淋巴瘤

Effect of ICE regimen in treatment of relapsed and refractory non-Hodgldn's lymphoma
原文传递
导出
摘要 目的探讨ICE方案(异环磷酰胺、卡铂、依托泊苷)治疗复发和难治性非霍奇金淋巴瘤(NHL)的近期疗效和不良反应。方法25例复发和难治性NHL采用ICE方案治疗,21d为1个周期。观察疗效和不良反应。结果25例均能评价疗效,总有效率76.0%(19/25),总缓解率(RR)为60.0%(15/25),毒副反应主要为白细胞和血小板减少,但均为可逆,未出现因化疗毒性而死亡患者。结论ICE方案是治疗复发和难治性NHL安全有效的解救方案,缓解率高,化疗耐受性好。 Objective To evaluate the short-term effect and side effects of ICE regimen treating the patients with relapsed and refractory non-Hodgkin's lymphoma(NHL). Methods Twenty-five patients with relapsed and refractory NHL were treated with ICE regimen. Treatment was repeated every 3 weeks. Results The total effective rate was 76.0% for 25 patients,The response rate(RR) was 60.0%. The main side effects were marrow suppression in- eluding of leucopenia and thromboeytopenia,no patients dead for toxic reactions of chemotherapy. Conclusion ICE regimen was a safe and effective salvage regimen for the patients with relapsed and refractory NHL.
出处 《中国基层医药》 CAS 2011年第18期2479-2480,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 淋巴瘤 非霍奇 化学疗法 Lymphoma,non-Hodgkin Chemotherapy
  • 相关文献

参考文献8

二级参考文献43

  • 1周生余,石远凯,何小慧,张频,董梅,黄鼎智,杨建良,张长弓,刘鹏,杨晟,冯奉仪.DICE方案治疗复发或耐药中高度恶性非霍奇金淋巴瘤[J].癌症,2005,24(4):465-469. 被引量:29
  • 2石远凯,于燕霞.非霍奇金淋巴瘤治疗进展[J].临床肿瘤学杂志,2006,11(7):481-485. 被引量:11
  • 3Inoue R, Natazuka T, Shimoyama M, et al. Feasibility of highdose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphomaz a pilot study[J]. Leuk Lymphoma, 2000, 36(3-4):315-321.
  • 4Multani P, White CA, Grillo Lopez A. Non Hodgkin's lymphoma: review of conventional treatments[J]. Curr Pharm Biotechnol, 2001, 2(4): 279-291.
  • 5Gisselhrecht C, Mounier N. Improving second-line therapy in aggressive non-Hodgkin's lymphoma[J]. Semin Oncol, 2004, 31(1):12-16.
  • 6Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuselarge B-cell lymphoma[J]. J Clin Oncol, 2005, 23 (18):4117-4126.
  • 7Witzens Harig M, Heilmann C, Hensel M, et al. Long-term following-up of patients with non-Hodgkin's lymphoma follow ing myeloablative therapy and autologous transplantation of CD34^+-selected peripheral blood progenitor cells [J].Stem Cells, 2007, 25(1) :228-235.
  • 8Coleman M, Leonard J, Shuster M W, et al. DICE(dexamethasone, etoposide, ifosfamide and cisplatin) infusional chemotherapy for refractory or replased non-Hodgkin's lymphoma(NHL) [J]. EurJ Haematol Suppl, 2001, 64:41-45.
  • 9Biagi J J, Herbert K E, Smith C, et al. A phase Ⅱ study of dexamethasone, ifosfamide, cisplatin and etoposide(DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma[J]. Leuk Lymphoma, 2005, 46(2): 197-206.
  • 10Blay J Y, Gomez F, Sebban C, et al. The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial [J]. Blood,1998,92(10): 3562-3568.

共引文献149

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部